ReviewFuture medicinal chemistry2025
Recent advances in the design, development and therapeutic applications of PPARγ agonists.
Review in Future medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Peroxisome proliferator-activated receptor gamma (PPARγ) as a mechano-metabolic transducer: coordinating lipid homeostasis through mechanical cues.Molecular biomedicine · 2026Review
- Semaglutide and pioglitazone restore airway mucosal homeostasis by resolvingFrontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peroxisome proliferator-activated receptor γ (PPARγ) is a ligand-dependent transcription factor that regulates the expressions of a variety of target genes related to glucose homeostasis. It has been recognized that PPARγ is a druggable target in modern drug discovery. In this review, the design of synthetic PPARγ agonists, and the development of synthetic PPARγ agonists of diverse scaffolds including thiazolidinediones (TZDs) and non-TZDs were illustrated. In addition, the recent advances and the therapeutic applications of reported synthetic PPARγ agonists were discussed including type 2 diabetes (T2DM), liver and inflammatory diseases, cancer, and neurological disorders within the past ten years using cellular and animal models and clinical studies. Our aim is to promote PPARγ agonists as a promising breakthrough point for addressing the therapy of different human disorders by inspiring additional scientific communities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.